| Literature DB >> 18243745 |
Yuichi Awamura1, Kazuyuki Uchida, Eri Arikawa-Hirasawa.
Abstract
Progressive muscle weakness beginning at 6 months of age was observed in a male Persian-mix cat. Muscle atrophy and joint contracture progressed over the next 3 years. The cat had developed gait difficulty at 8 months of age. The cat died at age of 5 years and 3 months due to an acute respiratory disorder. The clinical, laboratory, necropsy and histopathological findings of the cat were consistent with those of muscular dystrophy. The cat was diagnosed as having laminin alpha2 (merosin)-deficient muscular dystrophy on the basis of immunohistochemical findings. The cat was born in an inbred colony, and another related cat exhibited similar clinical signs. Few cases of laminin alpha2-deficient muscular dystrophy have been reported in cats, and this report provides additional information about the disease.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18243745 PMCID: PMC7129761 DOI: 10.1016/j.jfms.2007.11.003
Source DB: PubMed Journal: J Feline Med Surg ISSN: 1098-612X Impact factor: 2.015
Fig 1A castrated male Persian-mix cat at 2 years and 2 months of age. The cat is recumbent, and flexed contracture and muscle atrophy in the limbs are evident. Head and neck motion is relatively well preserved.
Fig 2Histopathology of the biceps muscle of the thigh. There is marked atrophy and a decrease in the number of muscle fibres, with severe diffuse infiltration by fatty tissues. The intramuscular nerve branches (arrows) and muscle spindles (arrow heads) supplying the area of the lesion are well preserved. The asterisks represent remaining muscle fibres (haematoxylin and eosin stain; bar = 200 μm).
Results of immunohistochemical staining
| Antibody | Controls | Affected cat |
|---|---|---|
| Dystrophin (monoclonal anti-human) | + | + |
| Dystrophin (monoclonal anti-human) | + | + |
| α-Dystroglycan (monoclonal anti-rabbit) | + | + |
| β-Dystroglycan (monoclonal anti-human) | + | + |
| α-Sarcoglycan (monoclonal anti-rabbit) | + | + |
| β-Sarcoglycan (monoclonal anti-human) | + | + |
| γ-Sarcoglycan (monoclonal anti-rabbit) | + | + |
| δ-Sarcoglycan (monoclonal anti-human) | + | + |
| δ-Sarcoglycan (polyclonal anti-human) | + | + |
| Emerin (monoclonal anti-human) | + | + |
| Laminin α2 1F9 (monoclonal anti-human) | + | − |
| Laminin α2 5H2 (monoclonal anti-human) | + | − |
+, Positive; −, negative.
Chemicon International Inc, Temecula, CA, USA.
Kamiya Biomedical Company, Seattle, WA, USA.
Upstate, Lake Placid, NY, USA.
YLEM, Roma, Italy.
Novocastra, Newcastle, UK.
Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA.
Provided by Eva Engvall, Burnham Institute for Medical Research, La Jolla, CA, USA.
Fig 3Immunofluorescence staining of muscles for laminin α2. (a) Control with 1F9 antibody, (b) affected muscle with 1F9 antibody, (c) control with 5H2 antibody and (d) affected muscle with 5H2 antibody. The green staining indicates positivity, and the lack of staining indicates negativity with the antibodies. The basement membranes of the affected muscles (b and d) are negative for the two monoclonal antibodies (1F9 and 5H2), whereas those of the controls (a and c) are intensely positive for both antibodies (bar = 100 μm).
Fig 4Family tree. The circles and boxes indicate females and males, respectively. The clear circles and boxes indicate clinically normal cats, and the coloured boxes indicate affected cats. The present cat and its siblings were inbred. There were two affected male cats (the present case and an affected sibling), two clinically normal male cats and two clinically normal female cats.